Dermata Therapeutics Stock Performance

DRMA Stock  USD 0.65  0.03  4.41%   
The firm shows a Beta (market volatility) of 0.83, which means possible diversification benefits within a given portfolio. As returns on the market increase, Dermata Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Dermata Therapeutics is expected to be smaller as well. At this point, Dermata Therapeutics has a negative expected return of -0.0487%. Please make sure to confirm Dermata Therapeutics' value at risk, rate of daily change, relative strength index, as well as the relationship between the kurtosis and market facilitation index , to decide if Dermata Therapeutics performance from the past will be repeated at some point in the near future.

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Dermata Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong primary indicators, Dermata Therapeutics is not utilizing all of its potentials. The newest stock price disturbance, may contribute to short-term losses for the investors. ...more
Last Split Factor
1:15
Last Split Date
2024-05-16
1
DRMA Substantial Cash Increase Enhances Financial Stability DRMA Stock News
05/14/2025
2
Dermata Therapeutics Price Target Cut Amid Capital Raise Plans DRMA Stock News
05/21/2025
3
Dermata Faces Nasdaq Delisting Risk, Plans Stock Split - TipRanks
07/07/2025
4
Dermata Therapeutics Stock Price, News Analysis - MarketBeat
07/11/2025
Begin Period Cash Flow7.4 M

Dermata Therapeutics Relative Risk vs. Return Landscape

If you would invest  71.00  in Dermata Therapeutics on April 21, 2025 and sell it today you would lose (6.00) from holding Dermata Therapeutics or give up 8.45% of portfolio value over 90 days. Dermata Therapeutics is currently does not generate positive expected returns and assumes 4.3463% risk (volatility on return distribution) over the 90 days horizon. In different words, 38% of stocks are less volatile than Dermata, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Dermata Therapeutics is expected to under-perform the market. In addition to that, the company is 5.2 times more volatile than its market benchmark. It trades about -0.01 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.29 per unit of volatility.

Dermata Therapeutics Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Dermata Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Dermata Therapeutics, and traders can use it to determine the average amount a Dermata Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = -0.0112

Best PortfolioBest Equity
Good Returns
Average Returns
Small Returns
CashSmall RiskAverage RiskHigh RiskHuge Risk
Negative ReturnsDRMA

Estimated Market Risk

 4.35
  actual daily
38
62% of assets are more volatile

Expected Return

 -0.05
  actual daily
0
Most of other assets have higher returns

Risk-Adjusted Return

 -0.01
  actual daily
0
Most of other assets perform better
Based on monthly moving average Dermata Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Dermata Therapeutics by adding Dermata Therapeutics to a well-diversified portfolio.

Dermata Therapeutics Fundamentals Growth

Dermata Stock prices reflect investors' perceptions of the future prospects and financial health of Dermata Therapeutics, and Dermata Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Dermata Stock performance.

About Dermata Therapeutics Performance

By analyzing Dermata Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Dermata Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Dermata Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Dermata Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Last ReportedProjected for Next Year
Return On Tangible Assets-3.5 K-3.3 K
Return On Capital Employed-8 K-7.6 K
Return On Assets-3.5 K-3.3 K
Return On Equity(7.87)(7.48)

Things to note about Dermata Therapeutics performance evaluation

Checking the ongoing alerts about Dermata Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Dermata Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Dermata Therapeutics generated a negative expected return over the last 90 days
Dermata Therapeutics has some characteristics of a very speculative penny stock
Dermata Therapeutics has high historical volatility and very poor performance
Dermata Therapeutics has a very high chance of going through financial distress in the upcoming years
Net Loss for the year was (12.29 M) with profit before overhead, payroll, taxes, and interest of 0.
Dermata Therapeutics currently holds about 10.63 M in cash with (11.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.05, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Dermata Therapeutics has a poor financial position based on the latest SEC disclosures
Roughly 18.0% of the company shares are held by company insiders
Latest headline from news.google.com: Dermata Therapeutics Stock Price, News Analysis - MarketBeat
Evaluating Dermata Therapeutics' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Dermata Therapeutics' stock performance include:
  • Analyzing Dermata Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Dermata Therapeutics' stock is overvalued or undervalued compared to its peers.
  • Examining Dermata Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Dermata Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Dermata Therapeutics' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Dermata Therapeutics' stock. These opinions can provide insight into Dermata Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Dermata Therapeutics' stock performance is not an exact science, and many factors can impact Dermata Therapeutics' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Dermata Stock analysis

When running Dermata Therapeutics' price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance